Thus, the expression and active engagement on T cells of CD27 by mAbs has the potential to positively affect adaptive immunotherapy against cancer (55), suggesting conversely that the pathological increase of T cells which lack CD27 expression could be a gradually increasing disadvantage. This evidence concerns the gene CD27 and cancer.